Amount of Award:

$10,000

Investigator:

Lauren Orenstein, MD, is Assistant Professor in the Department of Dermatology at Emory University School of Medicine

Race and Sex Disparities in Biologic Medication Prescription for Hidradenitis Suppurativa and Its
Influence on Opioid Use

Layman’s Statement:

Hidradenitis suppurativa (HS) is a chronic painful skin disease. Many patients with HS end up using opioids for
pain. The only FDA approved treatment for HS, adalimumab, has been shown to reduce HS pain. However, it
is unknown whether adalimumab decreases opioid use in HS. It is also unknown whether minorities have
equal access to this medication. Using the medical records of HS patients cared for in the Emory Health
System, we will assess if adalimumab prescriptions reduce opioid use and whether there are differences
between races in access to adalimumab prescriptions. This work has the potential to demonstrate racial
disparities in HS treatments and opportunities for reducing chronic pain and disability among patients with HS.

Back to Top